|
Baseline Characteristics
|
No Tourniquet (n = 1423)
|
Tourniquet use (n = 4902)
|
All patients (n = 6325)
|
P values
|
|---|
|
Demographic characteristics
|
|
Age (M ± SD)
|
66.67 ± 8.77
|
66.58 ± 8.74
|
66.60 ± 8.75
|
0.722
|
|
Female, N (%)
|
1099 (77.23%)
|
3872 (78.99%)
|
4971 (78.59%)
|
0.155
|
|
BMI
|
24.89 ± 3.56
|
25.83 ± 3.5.36
|
25.62 ± 5.02
|
0.000*
|
|
Diagnoses, N (%)
| | | |
0.145
|
|
OA
|
1321 (92.83%)
|
4603 (93.90%)
|
5924 (93.66%)
| |
|
Inflammatory arthritis
|
102 (7.17%)
|
299 (6.10%)
|
401 (6.34%)
| |
|
Comorbidities, N (%)
|
|
Hypertension
|
224 (15.74%)
|
1483 (30.25%)
|
1707 (26.99%)
|
0.000*
|
|
Type 2 diabetes
|
51 (3.58%)
|
382 (7.79%)
|
433 (6.85%)
|
0.000*
|
|
CHD
|
15 (1.05%)
|
202 (4.13%)
|
217 (3.43%)
|
0.000*
|
|
COPD
|
4 (0.28%)
|
30 (0.61%)
|
34 (0.54%)
|
0.133
|
|
Preoperative analgesic use N (%)
|
241 (16.94%)
|
1551 (31.64%)
|
1792 (28.33%)
|
0.000*
|
|
Preoperative laboratories
|
|
Preoperative Hb (g/L)
|
128.54 ± 15.24
|
132.04 ± 16.02
|
131.25 ± 15.91
|
0.000*
|
|
Preoperative ALB (g/L)
|
41.72 ± 2.54
|
40.86 ± 2.98
|
40.83 ± 2.89
|
0.095
|
|
Operative variables
|
|
Anesthesia, N (%)
| | | |
0.000*
|
|
General
|
1271 (89.32%)
|
3056 (62.34%)
|
4327 (68.41%)
| |
|
Regional
|
152 (10.68%)
|
1846 (37.66%)
|
1998 (31.59%)
| |
|
ASA class, N (%)
| | | |
0.007*
|
|
< 3
|
1303 (91.57%)
|
4367 (89.09%)
|
5670 (89.64%)
| |
|
≥ 3
|
120 (8.43%)
|
535 (10.91%)
|
655 (10.36%)
| |
|
TXA use N (%)
|
639 (44.91%)
|
2758 (56.26%)
|
3397 (53.71%)
|
0.000*
|
|
Drain use, N (%)
|
564 (39.63%)
|
3976 (81.11%)
|
4540 (71.78%)
|
0.000*
|
|
Intraoperative blood loss (mL)
|
168.43 ± 100.56
|
166.55 ± 97.71
|
166.97 ± 98.36
|
0.526
|
|
Operative time (min)
|
81.60 ± 27.28
|
87.32 ± 29.51
|
86.03 ± 29.12
|
0.000*
|
- BMI body mass index; OA osteoarthritis; CHD coronary heart disease; COPD chronic obstructive pulmonary disease; Hb hemoglobin; ALB albumin; ASA American Society of Anesthesiologists; TXA tranexamic acid. *: p < 0.05
